{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:25:42Z","timestamp":1780633542299,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014349","name":"Society For Maternal-Fetal Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ajog.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T03:41:58Z","timestamp":1631850118000},"page":"B9-B18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Society for Maternal-Fetal Medicine Special Statement: Beyond the scalpel: in utero fetal gene therapy and curative medicine"],"prefix":"10.1016","volume":"225","author":[{"given":"Matthew A.","family":"Shanahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti M.","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence B.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Chervenak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza A.","family":"Shamshirsaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.09.001_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajog.2021.09.001_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","article-title":"Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease","volume":"55","author":"Guilcher","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ajog.2021.09.001_bib4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/15265161.2020.1781970","article-title":"Germline gene editing for sickle cell disease","volume":"20","author":"Sharma","year":"2020","journal-title":"Am J Bioeth"},{"key":"10.1016\/j.ajog.2021.09.001_bib6","article-title":"Precision medicine approaches in sickle cell","volume":"5","author":"Gopal","year":"2019","journal-title":"J\u00a0Precis Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib7","article-title":"Unsickling the sickle: a review of state of the art and emerging applications of iPSCs and CRISPR\/Cas9 for gene editing solutions for sickle cell disease","volume":"5","author":"Dogra","year":"2019","journal-title":"J\u00a0Precis Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ajog.2021.09.001_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair? Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ajog.2021.09.001_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ajog.2021.09.001_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ajog.2021.09.001_bib12","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/mtna.2016.58","article-title":"CRISPR-Cas9 for in\u00a0vivo gene therapy: promise and hurdles","volume":"5","author":"Dai","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ajog.2021.09.001_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmedgenet-2014-102968","article-title":"CRISPR-Cas9: a new and promising player in gene therapy","volume":"52","author":"Xiao-Jie","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2021.09.001_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ajog.2021.09.001_bib15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib16","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2017-10-811505","article-title":"Induction of fetal hemoglobin synthesis by CRISPR\/Cas9-mediated editing of the human \u03b2-globin locus","volume":"131","author":"Antoniani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2021.09.001_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2021.09.001_bib18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav8375","article-title":"In utero gene editing for monogenic lung disease","volume":"11","author":"Alapati","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamapediatrics.2020.1519","article-title":"Gene and stem cell therapies for fetal care: a Review","volume":"174","author":"O\u2019Connell","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ajog.2021.09.001_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40291-020-00445-y","article-title":"The future of in utero gene therapy","volume":"24","author":"Peranteau","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.ajog.2021.09.001_bib22","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/mtm.2016.20","article-title":"In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application","volume":"5","author":"Almeida-Porada","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ajog.2021.09.001_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymthe.2019.02.015","article-title":"In utero gene therapy consensus statement from the IFeTIS","volume":"27","author":"Almeida-Porada","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajog.2021.09.001_bib24","author":"Porada"},{"key":"10.1016\/j.ajog.2021.09.001_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.siny.2017.05.003","article-title":"Fetal stem cell and gene therapy","volume":"22","author":"Witt","year":"2017","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/sj.mt.6300219","article-title":"Persistent expression of hF.IX after tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice","volume":"15","author":"Sabatino","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajog.2021.09.001_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171132","article-title":"Induction of immune tolerance to foreign protein via adeno-associated viral vector gene transfer in mid-gestation fetal sheep","volume":"12","author":"Davey","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2021.09.001_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ajog.2021.09.001_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/gt.2009.115","article-title":"The developmental stage determines the distribution and duration of gene expression after early intra-amniotic gene transfer using lentiviral vectors","volume":"17","author":"Endo","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajog.2021.09.001_bib30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nature22795","article-title":"Human fetal dendritic cells promote prenatal T-cell immune suppression through arginase-2","volume":"546","author":"McGovern","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2021.09.001_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41590-018-0294-9","article-title":"Memory CD4\u00a0+ T cells are generated in the human fetal intestine","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajog.2021.09.001_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3910","article-title":"Human fetal immune cells fight back","volume":"10","author":"Chougnet","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41591-020-0761-3","article-title":"Viable bacterial colonization is\u00a0highly limited in the human intestine in utero","volume":"26","author":"Rackaityte","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib34","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ajog.2021.09.001_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/sj.gt.3302632","article-title":"Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects","volume":"12","author":"Coutelle","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajog.2021.09.001_bib37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0995-864","article-title":"The challenge of fetal gene therapy","volume":"1","author":"Coutelle","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0095-5108(05)70036-1","article-title":"The switch from fetal to adult erythropoiesis","volume":"27","author":"Dame","year":"2000","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.ajog.2021.09.001_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/d41586-020-00053-0","article-title":"The kill-switch for CRISPR that could make gene-editing safer","volume":"577","author":"Dolgin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2021.09.001_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-61779-873-3_17","article-title":"Risks, benefits and ethical, legal, and societal considerations for translation of prenatal gene therapy to human application","volume":"891","author":"Coutelle","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajog.2021.09.001_bib41","first-page":"67","article-title":"Neonatal lymphedema from thoracic duct obstruction complicating percutaneous intravenous central catheterization","volume":"50","author":"Kylat","year":"2017","journal-title":"Lymphology"},{"key":"10.1016\/j.ajog.2021.09.001_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bpobgyn.2017.02.005","article-title":"Ethical issues in fetal therapy","volume":"43","author":"Moaddab","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2021.09.001_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/asheducation-2008.1.193","article-title":"Gene replacement therapy for sickle cell disease and other blood disorders","volume":"1","author":"Townes","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ajog.2021.09.001_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"key":"10.1016\/j.ajog.2021.09.001_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1737","article-title":"Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity","volume":"3","author":"Farooq","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.ajog.2021.09.001_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib48","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ajog.2021.09.001_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21443","article-title":"The cost of health care for patients with sickle cell disease","volume":"84","author":"Ballas","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajog.2021.09.001_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-med-041817-125507","article-title":"Emerging Genetic Therapy for sickle cell disease","volume":"70","author":"Orkin","year":"2019","journal-title":"Annu Rev Med"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821009972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821009972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:41Z","timestamp":1757590481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821009972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0002937821009972"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.09.001","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Society for Maternal-Fetal Medicine Special Statement: Beyond the scalpel: in utero fetal gene therapy and curative medicine","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}